Microbot Medical Inc. (MBOT) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Microbot Medical Inc. is a medical device company developing the LIBERTY® Endovascular Robotic System, a fully disposable robot for endovascular procedures. The company transitioned from a limited market release to a full market release in April 2026. Operations are primarily based in Israel, with a US office in Hingham, MA.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenues | $241 | $346 | $0 |
| Cost of Revenues | $(884) | $(987) | $0 |
| Gross Loss | $(643) | $(641) | $0 |
| Net Loss | $(5,627) | $(9,298) | $(6,101) |
| Net Loss Per Share (Diluted) | $(0.08) | $(0.14) | $(0.18) |
| Cash & Cash Equivalents | $3,152 | $3,152 | $4,082 |
| Marketable Securities | $64,215 | $64,215 | $74,680 |
| Total Current Assets | $72,173 | $72,173 | $79,822 |
| Total Current Liabilities | $3,888 | $3,888 | $3,421 |
| Net Working Capital | $68,285 | $68,285 | $76,401 |
Note: All financial figures are in thousands of U.S. dollars unless otherwise noted.
Material Changes vs. Prior Period
- Revenue Recognition: The company generated $346,000 in revenue for the six months ended June 30, 2026, compared to $0 in the prior year period. This marks the commencement of commercial sales following FDA 510(k) clearance in September 2025.
- Gross Loss: A gross loss of $641,000 was recorded for the six months ended June 30, 2026, driven by manufacturing costs exceeding early-stage revenues. No cost of revenue was recognized in 2025.
- Operating Expenses: Sales, General, and Administrative (SG&A) expenses increased significantly to $6.7 million (YTD 2026) from $3.2 million (YTD 2025), primarily due to hiring sales and marketing personnel and increased legal/operating costs for commercialization. R&D expenses decreased to $3.2 million (YTD 2026) from $3.6 million (YTD 2025), largely due to increased government grants and capitalization of manufacturing costs into inventory.
- Inventory Build-up: Inventory increased from $584,000 at year-end 2025 to $2.9 million at June 30, 2026, reflecting ramp-up for commercial sales.
- Cash Flow: Net cash used in operating activities increased to $10.0 million (YTD 2026) from $5.4 million (YTD 2025). Investing activities provided $9.5 million in 2026 (net sales of securities) compared to a use of $26.1 million in 2025 (net purchases).
Outlook, Risks, and Contingencies
- Liquidity: As of June 30, 2026, the company held approximately $67.4 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for more than 12 months.
- Geopolitical Risk: The company's R&D and operations are primarily in Israel. Ongoing regional conflict involving Israel, Iran, and the US poses risks regarding supply chain disruptions, workforce mobilization, and potential boycotts. The company currently reports no material adverse effect but monitors the situation closely.
- Regulatory Milestones: The company anticipates CE Mark approval in the second half of 2026 to enable marketing in Europe.
- Legal Proceedings: The company is involved in employment-related litigation with a former employee (Paul Mullen) in Massachusetts Superior Court. The company intends to defend against the claims.
- Subsequent Event: On July 28, 2026, the company acquired certain patents and assets from Forge Medical Inc. related to the VasoStat Hemostasis device. The purchase price is limited to potential royalties, capped at $5 million.
Key Facts for Investor Verification
- Commercial Viability: Verify the sustainability of revenue growth given the current gross loss (cost of revenue exceeding revenue) and the timeline to achieve positive gross margins.
- Cash Burn Rate: Monitor the rate of cash consumption as the company scales sales and marketing teams, despite the current 12-month liquidity runway.
- Geopolitical Exposure: Assess the potential impact of the Middle East conflict on the supply chain for the LIBERTY system, which is manufactured in Israel.
- Regulatory Timeline: Confirm the progress toward CE Mark approval expected in H2 2026.
- Inventory Valuation: Review the $2.9 million inventory balance for potential write-downs if commercial adoption does not meet projections.